Agile Therapeutics's Earnings: A Preview
Portfolio Pulse from Benzinga Insights
Agile Therapeutics (NASDAQ:AGRX) is scheduled to release its quarterly earnings report on March 22, 2024, with analysts expecting an EPS of $-0.54. The company's past earnings performance shows a pattern of beating EPS estimates but experiencing subsequent share price drops. Shares are currently trading at $0.579, marking a 95.04% decline over the last year. Investors are particularly focused on the company's guidance for future growth.
March 21, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Agile Therapeutics is expected to report an EPS of $-0.54 for the upcoming quarter, with a history of beating estimates but facing share price declines. Currently, shares have significantly dropped over the past year.
Given Agile Therapeutics' history of beating EPS estimates but experiencing subsequent share price declines, and the significant 95.04% drop in share price over the last year, it's likely that the upcoming earnings report could lead to further short-term negative impact on the stock price. The focus on future guidance as a key factor for stock movement is crucial, but given the negative trend, investor sentiment may remain bearish in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100